Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Immuno-genomic landscape of osteosarcoma.

Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA.

Nat Commun. 2020 Feb 21;11(1):1008. doi: 10.1038/s41467-020-14646-w.

PMID:
32081846
2.

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.

Kolb EA, Houghton PJ, Kurmasheva RT, Mosse YP, Maris JM, Erickson SW, Guo Y, Teicher BA, Smith MA, Gorlick R.

Pediatr Blood Cancer. 2020 Jan 23:e28098. doi: 10.1002/pbc.28098. [Epub ahead of print]

PMID:
31975571
3.

Assessment of patient experiences following total sacrectomy for primary malignant sacral tumors: A qualitative study.

Wang Y, Liang W, Qu S, Zhang Y, Du Z, Ji T, Qu H, Gorlick R, Guo W.

J Surg Oncol. 2019 Dec;120(8):1497-1504. doi: 10.1002/jso.25756. Epub 2019 Nov 8.

PMID:
31705571
4.

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.

Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, Lopez G, Vaksman Z, Mayoh C, Nance J, McCoy K, Haber M, Evans K, McCalmont H, Bendak K, Böhm JW, Marshall GM, Tyrrell V, Kalletla K, Braun FK, Qi L, Du Y, Zhang H, Lindsay HB, Zhao S, Shu J, Baxter P, Morton C, Kurmashev D, Zheng S, Chen Y, Bowen J, Bryan AC, Leraas KM, Coppens SE, Doddapaneni H, Momin Z, Zhang W, Sacks GI, Hart LS, Krytska K, Mosse YP, Gatto GJ, Sanchez Y, Greene CS, Diskin SJ, Vaske OM, Haussler D, Gastier-Foster JM, Kolb EA, Gorlick R, Li XN, Reynolds CP, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Raman P, Wheeler DA, Maris JM.

Cell Rep. 2019 Nov 5;29(6):1675-1689.e9. doi: 10.1016/j.celrep.2019.09.071.

5.

Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.

Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, Villalobos V, Randall RL, Gorlick R, Janeway KA.

Eur J Cancer. 2019 Nov;121:177-183. doi: 10.1016/j.ejca.2019.08.015. Epub 2019 Oct 3.

PMID:
31586757
6.

High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, Hawkins DS; Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators.

J Clin Oncol. 2019 Dec 1;37(34):3192-3202. doi: 10.1200/JCO.19.00915. Epub 2019 Sep 25.

PMID:
31553693
7.

Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor.

Hu J, Xia X, Gorlick R, Li S.

Oncogene. 2019 Dec;38(49):7433-7446. doi: 10.1038/s41388-019-0960-x. Epub 2019 Aug 19.

8.

Detection and targeting insulin growth factor receptor type 2 (IGF2R) in osteosarcoma PDX in mouse models and in canine osteosarcoma tumors.

Karkare S, Allen KJH, Jiao R, Malo ME, Dawicki W, Helal M, Godson DL, Dickinson R, MacDonald-Dickinson V, Yang R, Hoang B, Gorlick R, Geller DS, Dadachova E.

Sci Rep. 2019 Aug 7;9(1):11476. doi: 10.1038/s41598-019-47808-y.

9.

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.

Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD.

Cancer. 2019 Oct 15;125(20):3514-3525. doi: 10.1002/cncr.32351. Epub 2019 Jul 29. Review.

PMID:
31355930
10.

Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.

Zhao Q, Hu J, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S.

J Immunother Cancer. 2019 Jun 17;7(1):154. doi: 10.1186/s40425-019-0631-z.

11.

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force.

Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, Hingorani P.

F1000Res. 2019 Apr 15;8. pii: F1000 Faculty Rev-493. doi: 10.12688/f1000research.18139.1. eCollection 2019. Review.

12.

p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma.

Currier AW, Kolb EA, Gorlick RG, Roth ME, Gopalakrishnan V, Sampson VB.

Sci Rep. 2019 Apr 16;9(1):6161. doi: 10.1038/s41598-019-42450-0.

13.

LigaSure Use Decreases Intraoperative Blood Loss Volume and Blood Transfusion Volume in Sarcoma Surgery.

Levine NL, Zhang Y, Hoang BH, Yang R, Jurkowski ZH, Roth ME, Gill JB, Lo Y, Eisenberg RE, Bekarev M, Gorlick R, Geller DS.

J Am Acad Orthop Surg. 2019 Nov 15;27(22):841-847. doi: 10.5435/JAAOS-D-18-00144.

PMID:
30889038
14.

Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD.

Br J Cancer. 2019 Apr;120(8):869. doi: 10.1038/s41416-019-0424-7.

15.

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.

Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N.

Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25.

16.

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF.

Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18.

PMID:
30563935
17.

Challenges of Clinical Management of Adolescent and Young Adults With Bone and Soft Tissue Sarcoma.

Ferrari A, Gasparini P, Gill J, Gorlick R.

Cancer J. 2018 Nov/Dec;24(6):301-306. doi: 10.1097/PPO.0000000000000337. Review.

PMID:
30480574
18.

A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.

Isakoff MS, Goldsby R, Villaluna D, Krailo MD, Hingorani P, Collier A, Morris CD, Kolb EA, Doski JJ, Womer RB, Gorlick R, Janeway KA.

Pediatr Blood Cancer. 2019 Feb;66(2):e27524. doi: 10.1002/pbc.27524. Epub 2018 Oct 30.

19.

Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group.

Spraker-Perlman HL, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Doski J, Gorlick R, Janeway KA, Isakoff MS.

Pediatr Blood Cancer. 2019 Jan;66(1):e27444. doi: 10.1002/pbc.27444. Epub 2018 Sep 25.

20.

Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma.

Zhang Y, Zvi YS, Batko B, Zaphiros N, O'Donnell EF, Wang J, Sato K, Yang R, Geller DS, Koirala P, Zhang W, Du X, Piperdi S, Liu Y, Zheng D, Roth M, Gill J, Zhang J, Ren T, Gorlick R, Zi X, Hoang BH.

Sci Rep. 2018 Sep 24;8(1):14294. doi: 10.1038/s41598-018-32428-9.

21.

Dose Intensification Improves the Outcome of Ewing Sarcoma.

Gorlick R, Janeway KA, Adamson PC.

J Clin Oncol. 2018 Sep 12:JCO2018793489. doi: 10.1200/JCO.2018.79.3489. [Epub ahead of print] No abstract available.

PMID:
30204546
22.

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD.

Br J Cancer. 2018 Aug;119(5):615-621. doi: 10.1038/s41416-018-0212-9. Epub 2018 Aug 21. Erratum in: Br J Cancer. 2019 Apr;120(8):869.

23.

Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging.

Yedururi S, Chawla S, Amini B, Wei W, Salem UI, Morani AC, Wang WL, Gorlick R, Lewis VO, Daw NC.

Eur J Radiol. 2018 Aug;105:49-55. doi: 10.1016/j.ejrad.2018.05.021. Epub 2018 May 21.

24.

Detection of circulating tumor DNA in patients with osteosarcoma.

Barris DM, Weiner SB, Dubin RA, Fremed M, Zhang X, Piperdi S, Zhang W, Maqbool S, Gill J, Roth M, Hoang B, Geller D, Gorlick R, Weiser DA.

Oncotarget. 2018 Jan 18;9(16):12695-12704. doi: 10.18632/oncotarget.24268. eCollection 2018 Feb 27.

25.

DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas.

Wu SP, Cooper BT, Bu F, Bowman CJ, Killian JK, Serrano J, Wang S, Jackson TM, Gorovets D, Shukla N, Meyers PA, Pisapia DJ, Gorlick R, Ladanyi M, Thomas K, Snuderl M, Karajannis MA.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00031. Epub 2017 Oct 6.

26.

Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma.

Shaul E, Roth M, Lo Y, Geller DS, Hoang B, Yang R, Malkin D, Gorlick R, Gill J.

Cancer. 2018 Mar 15;124(6):1242-1250. doi: 10.1002/cncr.31212. Epub 2018 Jan 3.

27.

In vivo, noninvasive functional measurements of bone sarcoma using diffuse optical spectroscopic imaging.

Peterson HM, Hoang BH, Geller D, Yang R, Gorlick R, Berger J, Tingling J, Roth M, Gill J, Roblyer D.

J Biomed Opt. 2017 Dec;22(12):1-9. doi: 10.1117/1.JBO.22.12.121612.

28.

Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma.

Nakka M, Allen-Rhoades W, Li Y, Kelly AJ, Shen J, Taylor AM, Barkauskas DA, Yustein JT, Andrulis IL, Wunder JS, Gorlick R, Meltzer PS, Lau CC, Man TK; TARGET osteosarcoma consortium.

Oncotarget. 2017 May 27;8(57):96738-96752. doi: 10.18632/oncotarget.18236. eCollection 2017 Nov 14.

29.

Current and future therapeutic approaches for osteosarcoma.

Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R.

Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50. doi: 10.1080/14737140.2018.1413939. Epub 2017 Dec 14. Review.

PMID:
29210294
30.

Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.

Koster R, Panagiotou OA, Wheeler WA, Karlins E, Gastier-Foster JM, Caminada de Toledo SR, Petrilli AS, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Lecanda F, Serra M, Hattinger C, Picci P, Scotlandi K, Thomas DM, Ballinger ML, Gorlick R, Barkauskas DA, Spector LG, Tucker M, Belynda DH, Yeager M, Hoover RN, Wacholder S, Chanock SJ, Savage SA, Mirabello L.

Int J Cancer. 2018 Apr 15;142(8):1594-1601. doi: 10.1002/ijc.31195. Epub 2017 Dec 23.

31.

CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression.

Ren T, Piperdi S, Koirala P, Park A, Zhang W, Ivenitsky D, Zhang Y, Villanueva-Siles E, Hawkins DS, Roth M, Gorlick R.

Oncotarget. 2017 Sep 23;8(50):87848-87859. doi: 10.18632/oncotarget.21254. eCollection 2017 Oct 20.

32.

Provider views on the management of Ewing sarcoma of the spine and pelvis.

Zhu C, Olson KA, Roth M, Geller DS, Gorlick RG, Gill J, Laack NN, Randall RL.

J Surg Oncol. 2018 Mar;117(3):417-424. doi: 10.1002/jso.24860. Epub 2017 Oct 16.

PMID:
29044582
33.

Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.

Ahmed SK, Randall RL, DuBois SG, Harmsen WS, Krailo M, Marcus KJ, Janeway KA, Geller DS, Sorger JI, Womer RB, Granowetter L, Grier HE, Gorlick RG, Laack NNI.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1286-1294. doi: 10.1016/j.ijrobp.2017.08.020. Epub 2017 Aug 24.

34.

Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation.

Glover J, Man TK, Barkauskas DA, Hall D, Tello T, Sullivan MB, Gorlick R, Janeway K, Grier H, Lau C, Toretsky JA, Borinstein SC, Khanna C, Fan TM; COG Osteosarcoma Biology Group.

PLoS One. 2017 Jul 21;12(7):e0181204. doi: 10.1371/journal.pone.0181204. eCollection 2017.

35.

Mechanical analysis of the vascularized fibular graft prosthetic composite (VFGPC) for internal hemipelvectomy reconstruction.

Morris J, Yang R, Roth M, Gill J, Gorlick R, Lo Y, Hoang BH, Garfein E, Geller DS.

J Surg Oncol. 2017 Jun;115(7):864-869. doi: 10.1002/jso.24593. Epub 2017 May 22.

PMID:
28543392
36.

Clinical trial enrollment of adolescents and young adults with sarcoma.

Davis LE, Janeway KA, Weiss AR, Chen YE, Scharschmidt TJ, Krailo M, Glade Bender JL, Kopp LM, Patel SR, Schwartz GK, Horvath LE, Hawkins DS, Chuk MK, Reinke DK, Gorlick RG, Randall RL.

Cancer. 2017 Sep 15;123(18):3434-3440. doi: 10.1002/cncr.30757. Epub 2017 May 11. Review.

37.

Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model.

Yang Y, Yang R, Roth M, Piperdi S, Zhang W, Dorfman H, Rao P, Park A, Tripathi S, Freeman C, Zhang Y, Sowers R, Rosenblum J, Geller D, Hoang B, Gill J, Gorlick R.

Genes Cancer. 2017 Jan;8(1-2):484-494. doi: 10.18632/genesandcancer.133.

38.

The effect of bone morphogenetic protein-2 on osteosarcoma metastasis.

Gill J, Connolly P, Roth M, Chung SH, Zhang W, Piperdi S, Hoang B, Yang R, Guzik H, Morris J, Gorlick R, Geller DS.

PLoS One. 2017 Mar 6;12(3):e0173322. doi: 10.1371/journal.pone.0173322. eCollection 2017.

39.

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.

Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E, Gorlick R, Kolb EA.

Oncotarget. 2016 Dec 27;7(52):86594-86607. doi: 10.18632/oncotarget.13358.

40.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26304. Epub 2016 Oct 27.

41.

Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R).

Geller DS, Morris J, Revskaya E, Kahn M, Zhang W, Piperdi S, Park A, Koirala P, Guzik H, Hall C, Hoang B, Yang R, Roth M, Gill J, Gorlick R, Dadachova E.

Nucl Med Biol. 2016 Dec;43(12):812-817. doi: 10.1016/j.nucmedbio.2016.07.008. Epub 2016 Jul 30.

42.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26263. Epub 2016 Sep 21.

43.

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS.

Lancet Oncol. 2016 Oct;17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5. Epub 2016 Aug 25.

44.

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival.

Koirala P, Roth ME, Gill J, Chinai JM, Ewart MR, Piperdi S, Geller DS, Hoang BH, Fatakhova YV, Ghorpade M, Zang X, Gorlick R.

Sci Rep. 2016 Aug 17;6:31154. doi: 10.1038/srep31154.

45.

The case for informative phase 2 trials in osteosarcoma.

Janeway KA, Gorlick R.

Lancet Oncol. 2016 Aug;17(8):1022-1023. doi: 10.1016/S1470-2045(16)30293-5. No abstract available.

PMID:
27511145
46.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ.

Cancer Res. 2016 Oct 1;76(19):5798-5809. Epub 2016 Aug 5.

47.

Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling.

Cohen B, Roth M, Marron JM, Gray SW, Geller DS, Hoang B, Gorlick R, Janeway KA, Gill J.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):990-997. Epub 2016 Jul 26.

48.

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.

Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R.

Sci Rep. 2016 Jul 26;6:30093. doi: 10.1038/srep30093.

49.

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.

Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O 3rd, Widemann BC, Zwerdling T, Bomgaars L, Langevin AM, Grier HE, Weigel B, Blaney SM, Gorlick R, Janeway KA.

J Clin Oncol. 2016 Sep 1;34(25):3031-8. doi: 10.1200/JCO.2015.65.5381. Epub 2016 Jul 11.

50.

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.

Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Pápai Z, Rubino J, Pathiraja K, Hille DA, Ayers M, Yao SL, Nebozhyn M, Lu B, Mauro D.

Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. doi: 10.1002/pbc.26087. Epub 2016 Jun 30.

Supplemental Content

Loading ...
Support Center